

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2026;
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN
THE COMPOSITION OF THE BOARD COMMITTEES**

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The board of directors (the “**Directors**” and the “**Board**”, respectively) of MicroPort Scientific Corporation (the “**Company**”) is pleased to announce that all the proposed resolutions as set out in the notice of the annual general meeting of the Company (the “**AGM**”) dated 8 June 2026 were duly passed by the holders of the Company’s ordinary shares (the “**Shares**” and the “**Shareholders**” respectively) by way of a poll at the AGM held on 30 June 2026. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2025	423,275,029 (99.963843%)	153,100 (0.036157%)
2(i).	To re-elect Dr. Feng Gu as a non-executive Director of the Company	394,257,415 (93.110823%)	29,170,714 (6.889177%)
2(ii).	To re-elect Dr. Qingbing Men as a non-executive director of the Company	395,551,813 (93.416518%)	27,876,316 (6.583482%)
2(iii).	To re-elect Ms. Weiqin Sun as a non-executive director of the Company	391,816,729 (92.534412%)	31,611,400 (7.465588%)
2(iv).	To re-elect Mr. Jonathan H. Chou as an independent non-executive director of the Company	396,571,166 (93.657256%)	26,856,963 (6.342744%)
2(v).	To re-elect Dr. Guoen Liu as an independent non-executive director of the Company	396,571,166 (93.661680%)	26,836,963 (6.338320%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	To elect Dr. Yingyao Chen as an independent non-executive director of the Company	423,275,029 (99.963843%)	153,100 (0.036157%)
4.	To authorize the board of directors of the Company (the “ Board ”) to fix the respective directors’ remuneration	423,029,673 (99.905898%)	398,456 (0.094102%)
5.	To re-appoint KPMG as auditor and to authorize the Board to fix its remuneration	423,131,198 (99.929875%)	296,931 (0.070125%)
6.	To give a general mandate to the directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution	423,275,029 (99.963843%)	153,100 (0.036157%)
7.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution	376,648,119 (88.952078%)	46,780,010 (11.047922%)
8.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company	376,965,514 (89.027036%)	46,462,615 (10.972964%)

Notes:

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 8, all the proposed resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of Shares in issue was 1,917,386,655 Shares.
- (c) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (d) As at the date of the AGM, the trustee of the share award scheme of the Company holds in aggregate 686,961 Shares who was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules and on all the proposed resolutions pursuant to the terms of the share award scheme of the Company. As such, the total number of Shares entitling the holder to attend and vote on the resolutions at the AGM was 1,916,699,694 Shares.
- (e) None of the Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the AGM.

- (f) None of the Shareholders have stated their intention in the Company's circular dated 8 June 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company's branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (h) The following Directors attended the AGM, namely Dr. Zhaohua Chang, Dr. Feng Gu, Dr. Qingbing Men, Ms. Weiqin Sun, Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND THE CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board is pleased to announce that, with effect from the conclusion of the AGM, Dr. Yingyao Chen (“**Dr. Chen**”) has been elected as an independent non-executive Director of the Company. His biographical details are set out below:

Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development.

Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001.

Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.

Dr. Chen has confirmed: (a) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (b) that he does not have any past or present financial or other interest in the business of the Company or its subsidiaries, or any connection with any core connected person of the Company; and (c) that there are no other factors that may affect his independence.

Save as disclosed above, Dr. Chen did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling Shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the date of this announcement, Dr. Chen was not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

Dr. Chen will enter into a letter of appointment with the Company under which he will be appointed for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Chen's emolument will be determined by the Board from time to time under the authority granted to the Board by the shareholders and in accordance with the recommendation of the remuneration committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions. Dr. Chen will also be appointed as a member of the Strategic Committee of the Board.

There is no information which is disclosable nor is Dr. Chen involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Chen that need to be brought to the attention of the Shareholders.

The Board would like to welcome Dr. Chen for joining the Board.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 30 June 2026

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purpose only*